SCHEMBL6400972

SCHEMBL6400972

O=CN(O)[C@H](CS(=O)(=O)Cc1ccc2sccc2c1)c1ccc(F)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.35
CA2 P00918 1/20 0.35
CYP2A6 P11509 2/20 0.35
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
NTRK1 P04629 1/20 0.35
MET P08581 1/20 0.35
PIM1 P11309 1/20 0.35
FGFR1 P11362 1/20 0.35
PRKACA P17612 1/20 0.35
GRK5 P34947 1/20 0.35
MAP2K2 P36507 1/20 0.35
FLT3 P36888 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
CDK8 P49336 1/20 0.35
GSK3B P49841 1/20 0.35
CDK7 P50613 1/20 0.35
CDK9 P50750 1/20 0.35
RPS6KA3 P51812 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401597 1.00 CA12 (0.35) CA12CA2CYP2A6CHEK1AURKA
SCHEMBL6399715 0.90 MMP2 (0.39) CA12CA2CYP2A6CHEK1AURKA
SCHEMBL6400319 0.90 MMP2 (0.39) CA12CA2CYP2A6CHEK1AURKA
SCHEMBL6404841 0.89 OPRM1 (0.34) CA12CA2CYP2A6MMP2MMP9
SCHEMBL6404846 0.89 OPRM1 (0.34) CA12CA2CYP2A6MMP2MMP9
SCHEMBL6400431 0.88 CSNK2A1 (0.36) CYP2A6CHEK1AURKANTRK1MET
SCHEMBL6400440 0.88 CSNK2A1 (0.36) CYP2A6CHEK1AURKANTRK1MET
SCHEMBL6399628 0.87 CA2 (0.36) CA12CA2CYP2A6CHEK1AURKA
SCHEMBL6400479 0.87 CYP2A6 (0.33) CA12CA2CYP2A6KCNH2MCHR2
SCHEMBL6400486 0.87 CYP2A6 (0.33) CA12CA2CYP2A6KCNH2MCHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US claimed
EP-1289980-B1 BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES SMITHKLINE BEECHAM PLC (GB) 2004-11-17 EP claimed
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides CD22, CD2, NEU3 CA12 158/4885CA2 1247/4885CYP2A6 486/4885
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides CD22, CD2, NEU3 CA12 132/4885CA2 1162/4885CYP2A6 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.